Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study

被引：0

作者：

Wiendl, H. ^{[1
]}

De Stefano, N. ^{[2
]}

Barkhof, F. ^{[3
]}

Montalban, X. ^{[4
]}

Achiron, A. ^{[5
]}

Derfuss, T. ^{[6
]}

Chan, A. ^{[7
]}

Hodgkinson, S. ^{[8
]}

Prat, A. ^{[9
]}

Leocani, L. ^{[10
]}

Schmierer, K. ^{[11
]}

Sellebjerg, F. ^{[12
]}

Vermersch, P. ^{[13
]}

Jin, H. ^{[14
]}

Jaervinen, E. ^{[14
]}

Chudecka, A. ^{[15
]}

Gardner, L. ^{[16
]}

机构：

[1] Univ Munster, Inst Translat Neurol, Dept Neurol, Munster, Germany

[2] Univ Siena, Dept Med Surg & Neurosci, Siena, Italy

[3] Vrije Univ Amsterdam, Dept Radiol, Med Ctr, Amsterdam, Netherlands

[4] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Dept Neurol Neuroimmunol, Ctr Esclerosi Multiple Catalunya Cemcat, Barcelona, Spain

[5] Sheba Acad Med Ctr, Multiple Sclerosis Ctr, Ramat Gan, Israel

[6] Univ Hosp Basel, Dept Neurol, Basel, Switzerland

[7] Bern Univ, Univ Hosp Bern, Dept Neurol, Inselspital, Bern, Switzerland

[8] Univ New South Wales Med, Ingham Inst Appl Med Res, Sydney, Australia

[9] Univ Montreal, Dept Neurosci, Montreal, PQ, Canada

[10] Univ Vita Salute San Raffaele, Expt Neurophysiol Unit, Milan, Italy

[11] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, Ctr Neurosci Surg & Trauma, London, England

[12] Rigshosp, Dept Neurol, Danish MS Ctr, Copenhagen Univ Hosp, Glostrup, Denmark

[13] Univ Lille, INSERM, U1172, LilNCog,CHU Lille,FHU Precise, Lille, France

[14] Healthcare Business Merck KGaA, Darmstadt, Germany

[15] Cytel Inc, Geneva, Switzerland

[16] EMD Serono Inc, Billerica, MA USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P008

引用

页码：21 / 22

页数：2

共 50 条

[11] Long-term effectiveness of cladribine tablets over 4 years in relapsing multiple sclerosis: Results from the MAGNIFY-MS Extension study
De Stefano, Nicola
Vermersch, Patrick
Wiendl, Heinz
Barkhof, Frederik
Montalban, Xavier
Achiron, Anat
Derfuss, Tobias
Chan, Andrew
Prat, Alexandre
Leocani, Letizia
Schmierer, Klaus
Sellebjerg, Finn
Lehn, Annette
Smyk, Andrzej
Nolting, Axel
Koelbach, Ralf
Hodgkinson, Suzanne
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 374 - 376
[12] Reduction in CUA MRI Lesions in the First 6 Months after Cladribine Tablets Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS Subgroup Analysis
De Stefano, Nicola
Barkhof, Frederik
Montalban, Xavier
Achiron, Anat
Derfuss, Tobias
Chan, Andrew
Hodgkinson, Suzanne
Prat, Alexandre
Leocani, Letizia
Schmierer, Klaus
Sellebjerg, Finn
Vermersch, Patrick
Wiendl, Heinz
Keller, Birgit
Roy, Sanjeev
NEUROLOGY, 2021, 96 (15)
[13] Treatment satisfaction in patients with highly-active relapsing multiple sclerosis treated with cladribine tablets: clarify-ms study interim analysis
Brochet, B.
Hupperts, R. H. Raymond
Langdon, D.
Solari, A.
Piehl, F.
Lechner-Scott, J.
Montalban, X.
Selmaj, K.
Valis, M.
Rejdak, K.
Havrdova, E. Kubala
Patti, F.
Alexandri, N.
Nolting, A.
Keller, B.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 623 - 623
[14] Treatment Satisfaction in Patients with Highly-active Relapsing Multiple Sclerosis Treated with Cladribine Tablets: CLARIFY-MS Study Interim Analysis
Brochet, Bruno
Hupperts, Raymond
Langdon, Dawn
Solari, Alessandra
Piehl, Fredrik
Lechner-Scott, Jeanette
Montalban, Xavier
Selmaj, Krzysztof
Valis, Martin
Havrdova, Eva
Rejdak, Konrad
Patti, Francesco
Alexandri, Nektaria
Nolting, Axel
Keller, Birgit
NEUROLOGY, 2021, 96 (15)
[15] Reduction of Neuroaxonal Damage in Patients With Highly Active Relapsing MS Treated With Cladribine Tablets
Schmierer, Klaus
Wiendl, Heinz
Barkhof, Frederik
Montalban, Xavier
Achiron, Anat
Derfuss, Tobias
Chan, Andrew
Hodgkinson, Suzanne
Prat, Alexandre
Leocani, Letizia
Sellebjerg, Finn
Vermersch, Patrick
Kuhle, Jens
Jin, Hulin
Jarvinen, Elina
Kloetgen, Andreas
Gardner, Lidia
De Stefano, Nicola
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 882 - 884
[16] Effect of 2-year cladribine treatment on brain volume in highly active relapsing MS patients
Warszawer, Yehuda
Nissan, Yael
Achiron, Anat
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 967 - 968
[17] Cladribine tablets in relapsing-remitting multiple sclerosis: study design of the 2-year, Phase IIIb CLARITY (CLAdRibine tablets Treating multiple sclerosis orallY) extension study
Rieckmann, Peter
Giovannoi, Gavin
Cook, Stuart D.
Greenberg, S.
Chang, Peter
Comi, Giancarlo
Sorensen, Per Soelberg
Vermersch, Patrick
MULTIPLE SCLEROSIS, 2008, 14 : S161 - S162
[18] 2-year follow-up of Finnish multiple sclerosis patients treated with cladribine tablets
Rauma, I.
Viitala, M.
Atula, S.
Kuusisto, H.
Sipila, J.
Ryytty, M.
Soilu-Hanninen, M.
Jarvinen, E.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 586 - 587
[19] Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summary
Brochet, Bruno
Solari, Alessandra
Lechner-Scott, Jeannette
Piehl, Fredrik
Langdon, Dawn
Hupperts, Raymond
Selmaj, Krzysztof
Patti, Francesco
Brieva, Luis
Maidal, Eva Maria
Alexandri, Nektaria
Smyk, Andrzej
Nolting, Axel
Montalban, Xavier
Havrdova, Eva Kubala
CLARIFY-MS Investigators
NEURODEGENERATIVE DISEASE MANAGEMENT, 2024, 14 (06) : 193 - 201
[20] Improvements in quality of life over 2 years in patients treated with cladribine tablets for highly active relapsing multiple sclerosis: Final analysis of CLARIFY-MS
Solari, A.
Montalban, X.
Lechner-Scott, J.
Piehl, F.
Brochet, B.
Langdon, D.
Hupperts, R.
Selmaj, K.
Havrdova, E. K.
Patti, F.
Brieva, L.
Maida, E. M.
Alexandri, N.
Smyk, A.
Nolting, A.
Keller, B.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 203 - 204

← 1 2 3 4 5 →